Evidence Level
Collagen Type II is a well-documented supplement for joint health, particularly in alleviating symptoms associated with osteoarthritis. Hydrolyzed type II collagen has shown efficacy in reducing activity-related joint pain and improving knee function. Clark et al. (2008) demonstrated that 10g/day of hydrolyzed type II collagen over 24 weeks significantly reduced joint pain in athletes. Bruyere et al. (2012) found benefits at a lower dose of 1,200mg in knee OA patients, while a meta-analysis by Zhu et al. (2018) confirmed statistically significant improvements in WOMAC scores across five RCTs.
The mechanism of action involves bioactive peptides, such as prolyl-hydroxyproline and hydroxyprolyl-glycine, which are absorbed intact and accumulate in cartilage. These peptides stimulate chondrocytes to produce new type II collagen and proteoglycans, enhancing joint health. Vitamin C enhances this process by supporting the hydroxylation of proline residues essential for collagen structure.
Recent studies further support its efficacy. Alekseeva et al. (2024) found undenatured type II collagen improved knee OA symptoms in a randomized trial of 212 patients. Fladerer-Grollitsch et al. (2025) demonstrated that a cartilage-supporting supplement, including Collagen Type II, improved knee OA symptoms and quality of life in a pilot study. However, Laky et al. (2024) found no significant differences in patient-reported outcomes for lumbar osteochondrosis but noted increased intervertebral disc volume on MRI.
Overall, Collagen Type II is supported by moderate evidence as an effective supplement for joint health, with benefits demonstrated across multiple studies and mechanisms of action.